Paola Picotti

Paola Picotti

Auto-generated profile, based on publicly available information

Paola Picotti

Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2012 in Nature Methods
Verified
Journal Article
Closed access
PDF file
PPPaola Picotti
Paola Picotti
RARuedi Aebersold
Ruedi Aebersold

1 January 2018 in Cell
Verified
Journal Article
Closed access
IPIlaria Piazza
Ilaria Piazza
KKKarl Kochanowski
Karl Kochanowski
VCValentina Cappelletti
Valentina Cappelletti
TFTobias Fuhrer
Tobias Fuhrer
ENElad Noor
Elad Noor
PPPaola Picotti
Paola Picotti

24 February 2017 in Science
Verified
Journal Article
Closed access
PDF file
PLPascal Leuenberger
Pascal Leuenberger
SGStefan Ganscha
Stefan Ganscha
Abdullah KahramanAbdullah Kahraman
Abdullah Kahraman
VCValentina Cappelletti
Valentina Cappelletti
PBPaul J. Boersema
Paul J. Boersema
PPPaola Picotti
Paola Picotti
How proteomes take the heat: Living organisms are very sensitive to temperature, and much of this is attributed to its effect on the structure and function of proteins. Leuenberger et al. explored thermostability on a proteome-wide scale in bacteria, yeast, and human cells by using a combination of limited proteolysis and mass spectrometry (see the Perspective by Vogel). Their results suggest that temperature-induced cell death is caused by the loss of a subset of proteins with key functions. The study also provides insight into the molecular and evolutionary bases of protein and proteome stability. Science , this issue p. eaai7825 ; see also p. 794

20 January 2013 in Nature
Verified
Journal Article
Closed access
PDF file
PPPaola Picotti
Paola Picotti
MCMathieu Clément-Ziza
Mathieu Clément-Ziza
HLHenry Lam
Henry Lam
DCDavid S. Campbell
David S. Campbell
ASAlexander Schmidt
Alexander Schmidt
RARuedi Aebersold
Ruedi Aebersold

17 October 2014 in Genome Medicine
Verified
Journal Article
Open access
MGMika Gustafsson
Mika Gustafsson
CNColm Nestor
Colm Nestor
HZHuan Zhang
Huan Zhang
ABAlbert-László Barabási
Albert-László Barabási
SBSergio Baranzini
Sergio Baranzini
MBMikael Benson
Mikael Benson
Many common diseases, such as asthma, diabetes or obesity, involve altered interactions between thousands of genes. High-throughput techniques (omics) allow identification of such genes and their products, but functional understanding is a formidable challenge. Network-based analyses of omics data have identified modules of disease-associated genes that have been used to obtain both a systems level and a molecular understanding of disease mechanisms. For example, in allergy a module was used to find a novel candidate gene that was validated by functional and clinical studies. Such analyses play important roles in systems medicine. This is an emerging discipline that aims to gain a translational understanding of the complex mechanisms underlying common diseases. In this review, we will explain and provide examples of how network-based analyses of omics data, in combination with functional and clinical studies, are aiding our understanding of disease, as well as helping to prioritize diagnostic markers or therapeutic candidate genes. Such analyses involve significant problems and limitations, which will be discussed. We also highlight the steps needed for clinical implementation.

21 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
IPIlaria Piazza
Ilaria Piazza
NBNigel Beaton
Nigel Beaton
RBRoland Bruderer
Roland Bruderer
TKThomas Knobloch
Thomas Knobloch
CBCrystel Barbisan
Crystel Barbisan
LRLukas Reiter
Lukas Reiter
Chemoproteomics is a key technology to characterize the mode of action of drugs, as it directly identifies the protein targets of bioactive compounds and aids in the development of optimized small-molecule compounds. Current approaches cannot identify the protein targets of a compound and also detect the interaction surfaces between ligands and protein targets without prior labeling or modification. To address this limitation, we here develop LiP-Quant, a drug target deconvolution pipeline based on limited proteolysis coupled with mass spectrometry that works across species, including in human cells. We use machine learning to discern features indicative of drug binding and integrate them into a single score to identify protein targets of small molecules and approximate their binding sites. We demonstrate drug target identification across compound classes, including drugs targeting kinases, phosphatases and membrane proteins. LiP-Quant estimates the half maximal effective concentration of compound binding sites in whole cell lysates, correctly discriminating drug binding to homologous proteins and identifying the so far unknown targets of a fungicide research compound.